What is the primary cardiac condition associated with anthracyclines?

What is the primary cardiac condition associated with anthracyclines?

• A. Hypertrophic cardiomyopathy
• B. Pericardial effusion
• C. Valvular disease
• D. Reduced myocardial contractility leading to cardiomyopathy

Answer: (D)

Anthracyclines primarily cause cardiotoxicity that targets the heart’s pumping ability. The hallmark is a dose-dependent loss of myocardial contractility, which over time leads to dilated cardiomyopathy and systolic heart failure. This manifests as a reduced ejection fraction and heart failure symptoms, and it is related to oxidative stress and damage to cardiac myocytes with cumulative dose. Other cardiac effects listed are not the typical primary outcome of anthracycline exposure: hypertrophic cardiomyopathy involves thickened heart walls from genetic or other causes, not drug-induced injury; pericardial effusion is fluid around the heart rather than an intrinsic pumping problem; valvular disease can occur from various etiologies but is not the classic consequence of anthracyclines.

Anthracyclines primarily cause cardiotoxicity that targets the heart’s pumping ability. The hallmark is a dose-dependent loss of myocardial contractility, which over time leads to dilated cardiomyopathy and systolic heart failure. This manifests as a reduced ejection fraction and heart failure symptoms, and it is related to oxidative stress and damage to cardiac myocytes with cumulative dose.

Other cardiac effects listed are not the typical primary outcome of anthracycline exposure: hypertrophic cardiomyopathy involves thickened heart walls from genetic or other causes, not drug-induced injury; pericardial effusion is fluid around the heart rather than an intrinsic pumping problem; valvular disease can occur from various etiologies but is not the classic consequence of anthracyclines.